![](/wp-content/uploads/2018/10/UkKPgLSmT7W33bCOLCuq.png)
$599
New Zafgen Data Suggests Clinical Hold Will Remain; Strategic Options to be Explored
Zafgen announced that it is planning to “strategic options to maximize shareholder value,” including a merger, acquisition, or in-licensing opportunity. Following preliminary data from a new animal study, Zafgen believes that in the short-term, there is a low probability of resolving the clinical hold placed on ZGN-1061. Below, FENIX provides brief thoughts on potential outcomes for Zafgen and ZGN-1061.